

Narciclasine

Catalog No: tcsc1051



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

29477-83-6

Formula:

$C_{14}H_{13}NO_7$

Pathway:

TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage

Target:

ROCK;ROCK;ROCK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 26 mg/mL (84.62 mM)

Alternative Names:

Lycoricidinol

Observed Molecular Weight:

307.26


Product Description

Narciclasine is a plant growth modulator. Narciclasine modulates the Rho/Rho kinase/LIM kinase/cofilin signaling pathway, greatly increasing GTPase RhoA activity as well as inducing actin stress fiber formation in a RhoA-dependent manner.

IC50 & Target: Rho^[1]

In Vitro: Narciclasine activates Rho and stress fibers in glioblastoma multiforme cells. The mean IC₅₀ of ~50 nM calculated on the 6 human glioblastoma multiforme (U373, Hs683, GL19, GL5, GL16, GL17), The mean IC₅₀ value of 47 nM for Narciclasine across a panel of 60 cancer cell lines^[1]. Bioassay-guided fractionation of the *A. belladonna* extract resulted in the identification of lycorine as the bio-active compound. The IC₅₀ measured for radicle growth inhibition is 0.1 μM for Narciclasine^[2].

In Vivo: The i.v. regimen of Narciclasine at 1 mg/kg significantly (P=0.02) increases the survival of GL19 glioblastoma multiforme-bearing mice. Narciclasine when given orally at the same dose five times a week for 5 consecutive weeks also significantly increases animal survival in this model (P=0.008). Oral treatment with Narciclasine at 1 mg/kg significantly increases the survival (P=0.004) of Hs683 glioblastoma multiforme-bearing mice. Increasing the number of doses administered per week does not increase the survival of these Hs683 glioblastoma multiforme-bearing mice. Narciclasine appears to show similar increased survival in these models to temozolomide but at appreciable lower doses and following both oral and i.v. administration^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!